NPHLA Daily
NPHLA Daily
Thursday, October 29, 2026 · 4-minute read
Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.
Top development today
What changed today in Metabolic: 6 trial updates
NPHLA tracked 6 new official records on this desk today: 6 trial updates. First: New trial registered: JOULE3 (Mechanisms of Weight Loss: Tirzepatide vs Semaglutide)
Metabolic signal
New trial registered: A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China
Phase 4, Novo Nordisk A/S. Conditions: Cardiovascular Risk; Chronic Kidney Disease. Interventions: Semaglutide. Investigational: trial-stage therapies are not approved for the use studied.
Aesthetics & Longevity signal
What changed today in Aesthetics & Longevity: 2 trial updates
NPHLA tracked 2 new official records on this desk today: 2 trial updates. First: New trial registered: Comparative Analysis of Intralesional Platelet-Rich Plasma, NPH Insulin, and Vitamin C- A New Horizon and Future Hope for Linear Atrophic Scar…
AI & Technology signal
What changed today in AI & Technology: 1 new study
NPHLA tracked 1 new official record on this desk today: 1 new study. First: New research in Journal of medical Internet research: “Development and Pilot Evaluation of a Standardized and Accessible Rubric (OMNI) for Assessing Generative AI in Health Care Contexts: Four-Stage…
One thing worth watching
Comments close: Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and…
October 29, 2026 — verified from the Federal Register comments_close_on.
5 things to know
- What changed today in Metabolic: 6 trial updates
- What changed today in Aesthetics & Longevity: 2 trial updates
- What changed today in AI & Technology: 1 new study
- New trial registered: A Research Study Looking at Kidney and Heart Health in Adults With Type 2 Diabetes and Chronic Kidney Disease Treated With Semaglutide in China (ClinicalTrials.gov (U.S. National Library of…
- Results posted on ClinicalTrials.gov: A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics (ClinicalTrials.gov (U.S. National Library of Medicine))
Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.